Review

Division of Genetics, National Cancer Center, Research Institute 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Published Online:25 Feb 2015https://doi.org/10.2217/pgs.14.171

Abstract

Tamoxifen has been used not only for the treatment or prevention of recurrence in patients with estrogen receptor positive breast cancers but also for recurrent breast cancer. Because CYP2D6 is known to be an important enzyme responsible for the generation of the potent tamoxifen metabolite, ‘endoxifen’, lots of studies reported that genetic variation which reduced its enzyme activity were associated with poor clinical outcome of breast cancer patients treated with tamoxifen. However, there are some discrepant reports questioning the association between CYP2D6 genotype and clinical outcome after tamoxifen therapy. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes provides the evidence that dose adjustment is useful for the patients carrying reduced or null allele of CYP2D6 to maintain the effective endoxifen level. This review describes critical issues in pharmacogenomic studies as well as summarizes the results of the association of CYP2D6 genotype with tamoxifen efficacy.

Keywords:

References

1 Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793), 771–784 (2011).Crossref, Medline, Google Scholar
2 Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869), 805–816 (2013).Crossref, Medline, CAS, Google Scholar
3 Borgna Jl, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 256(2), 859–868 (1981).Crossref, Medline, CAS, Google Scholar
4 Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49(8), 2175–2183 (1989).Medline, CAS, Google Scholar
5 Johnson MD, Zuo H, Lee KH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85(2), 151–159 (2004).Crossref, Medline, CAS, Google Scholar
6 CYP2D6 allele nomenclature. www.cypalleles.ki.se/cyp2d6.htm Google Scholar
7 Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284–295 (1997).Medline, CAS, Google Scholar
8 Griese Eu, Zanger UM, Brudermanns U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8(1), 15–26 (1998).Crossref, Medline, CAS, Google Scholar
9 Irvin WJ Jr, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29(24), 3232–3239 (2011).Crossref, Medline, CAS, Google Scholar
10 Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 10(8), 545–558 (1991).Crossref, Medline, CAS, Google Scholar
11 Madlensky L, Natarajan L, Tchu S et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89(5), 718–725 (2011).Crossref, Medline, CAS, Google Scholar
12 Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99(5), 995–999 (2008).Crossref, Medline, CAS, Google Scholar
13 Hosono N, Kato M, Kiyotani K et al. CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin. Chem. 55(8), 1546–1554 (2009).Crossref, Medline, CAS, Google Scholar
14 Kiyotani K, Mushiroda T, Imamura CK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28(8), 1287–1293 (2010).Crossref, Medline, CAS, Google Scholar
15 Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113–121 (2007).Crossref, Medline, CAS, Google Scholar
16 Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429–1436 (2009).Crossref, Medline, CAS, Google Scholar
17 Province MA, Goetz MP, Brauch H et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin. Pharmacol. Ther. 95(2), 216–227 (2014).Crossref, Medline, CAS, Google Scholar
18 Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25(25), 3837–3845 (2007).Crossref, Medline, CAS, Google Scholar
19 Kiyotani K, Mushiroda T, Imamura CK et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res. Treat. 131(1), 137–145 (2012).Crossref, Medline, CAS, Google Scholar
20 Martinez De Duenas E, Ochoa Aranda E, Blancas Lopez-Barajas I et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype. Breast 23(4), 400–406 (2014).Crossref, Medline, Google Scholar
21 Regan MM, Leyland-Jones B, Bouzyk M et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J. Natl Cancer Inst. 104(6), 441–451 (2012).Crossref, Medline, CAS, Google Scholar
22 Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91(3), 249–258 (2005).Crossref, Medline, CAS, Google Scholar
23 Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9(1), R7 (2007).Crossref, Medline, Google Scholar
24 Hertz Dl, Mcleod Hl, Irvin WJ Jr. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 17(5), 620–630 (2012).Crossref, Medline, CAS, Google Scholar
25 Ingle JN, Suman VJ, Johnson PA et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res. 5(7), 1642–1649 (1999).Medline, CAS, Google Scholar
26 Stearns V, Johnson Md, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95(23), 1758–1764 (2003).Crossref, Medline, CAS, Google Scholar
27 Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30–39 (2005).Crossref, Medline, CAS, Google Scholar
28 Clarke R, Liu MC, Bouker KB et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22(47), 7316–7339 (2003).Crossref, Medline, CAS, Google Scholar
29 Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 48(8), 2304–2308 (1988).Medline, CAS, Google Scholar
30 Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310(3), 1062–1075 (2004).Crossref, Medline, CAS, Google Scholar
31 Gjerde J, Hauglid M, Breilid H et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol. 19(1), 56–61 (2008).Crossref, Medline, CAS, Google Scholar
32 Falany JL, Pilloff DE, Leyh TS, Falany CN. Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab. Dispos. 34(3), 361–368 (2006).Crossref, Medline, CAS, Google Scholar
33 Nishiyama T, Ogura K, Nakano H et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem. Pharmacol. 63(10), 1817–1830 (2002).Crossref, Medline, CAS, Google Scholar
34 Ogura K, Ishikawa Y, Kaku T et al. Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem. Pharmacol. 71(9), 1358–1369 (2006).Crossref, Medline, CAS, Google Scholar
35 Sun D, Sharma AK, Dellinger RW et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab. Dispos. 35(11), 2006–2014 (2007).Crossref, Medline, CAS, Google Scholar
36 Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6–13 (2005).Crossref, Medline, CAS, Google Scholar
37 Gross AS, Kroemer Hk, Eichelbaum M. Genetic polymorphism of drug metabolism in humans. Adv. Exp. Med. Biol. 283, 627–640 (1991).Crossref, Medline, CAS, Google Scholar
38 Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17(2), 93–101 (2007).Crossref, Medline, CAS, Google Scholar
39 Sideras K, Ingle JN, Ames MM et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J. Clin. Oncol. 28(16), 2768–2776 (2010).Crossref, Medline, CAS, Google Scholar
40 Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80(1), 61–74 (2006).Crossref, Medline, CAS, Google Scholar
41 Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356(9247), 2059–2063 (2000).Crossref, Medline, CAS, Google Scholar
42 Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. 20(6), 1578–1583 (2002).Crossref, Medline, CAS, Google Scholar
43 Stearns V, Beebe Kl, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289(21), 2827–2834 (2003).Crossref, Medline, CAS, Google Scholar
44 Orleans RJ, Li L, Kim MJ et al. FDA approval of paroxetine for menopausal hot flushes. N. Engl. J. Med. 370(19), 1777–1779 (2014).Crossref, Medline, CAS, Google Scholar
45 Zembutsu H, Sasa M, Kiyotani K, Mushiroda T, Nakamura Y. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev. Anticancer Ther. 11(2), 185–193 (2011).Crossref, Medline, CAS, Google Scholar
46 Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol. Biomarkers Prev. 18(9), 2562–2564 (2009).Crossref, Medline, CAS, Google Scholar
47 Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010(8), 340 (2010).Google Scholar
48 Siegelmann-Danieli N, Kurnik D, Lomnicky Y et al. Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res. Treat. 125(2), 505–510 (2011).Crossref, Medline, CAS, Google Scholar
49 Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas 67(4), 296–308 (2010).Crossref, Medline, CAS, Google Scholar
50 Dezentje VO, Van Blijderveen NJ, Gelderblom H et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol. 28(14), 2423–2429 (2010).Crossref, Medline, CAS, Google Scholar
51 Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010. Breast Cancer Res. Treat. 137(1), 285–296 (2013).Crossref, Medline, Google Scholar
52 Higgins Mj, Stearns V. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr. Oncol. Rep. 12(1), 7–15 (2010).Crossref, Medline, CAS, Google Scholar
53 Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7(3), R284–R290 (2005).Crossref, Medline, CAS, Google Scholar
54 Xu Y, Sun Y, Yao L et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19(8), 1423–1429 (2008).Crossref, Medline, CAS, Google Scholar
55 Ramon Y, Cajal T, Altes A, Pare L et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res. Treat. 119(1), 33–38 (2010).Crossref, Medline, Google Scholar
56 Abraham JE, Maranian MJ, Driver KE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 12(4), R64 (2010).Crossref, Medline, Google Scholar
57 Goetz MP, Suman VJ, Hoskin TL et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin. Cancer Res. 19(2), 500–507 (2013).Crossref, Medline, CAS, Google Scholar
58 Newman WG, Hadfield KD, Latif A et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res. 14(18), 5913–5918 (2008).Crossref, Medline, CAS, Google Scholar
59 Teh LK, Mohamed NI, Salleh MZ et al. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J. 14(1), 52–59 (2012).Crossref, Medline, CAS, Google Scholar
60 Sirachainan E, Jaruhathai S, Trachu N et al. CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmgenomics Pers. Med. 5, 149–153 (2012).Medline, CAS, Google Scholar
61 Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother. Pharmacol. 70(1), 75–81 (2012).Crossref, Medline, CAS, Google Scholar
62 Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 115(5), 952–961 (2009).Crossref, Medline, CAS, Google Scholar
63 Stingl JC, Parmar S, Huber-Wechselberger A et al. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr. Med. Res. Opin. 26(11), 2535–2542 (2010).Crossref, Medline, CAS, Google Scholar
64 Kiyotani K, Mushiroda T, Hosono N et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet. Genomics 20(9), 565–568 (2010).Crossref, Medline, CAS, Google Scholar
65 Lash TL, Cronin-Fenton D, Ahern TP et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J. Natl Cancer Inst. 103(6), 489–500 (2011).Crossref, Medline, CAS, Google Scholar
66 Park Ih, Ro J, Park S et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res. Treat. 131(2), 455–461 (2012).Crossref, Medline, CAS, Google Scholar
67 Park HS, Choi JY, Lee MJ et al. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J. Korean Med. Sci. 26(8), 1007–1013 (2011).Crossref, Medline, Google Scholar
68 Thompson AM, Johnson A, Quinlan P et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 125(1), 279–287 (2011).Crossref, Medline, CAS, Google Scholar
69 Rae JM, Drury S, Hayes DF et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl Cancer Inst. 104(6), 452–460 (2012).Crossref, Medline, CAS, Google Scholar
70 Kiyotani K, Mushiroda T, Zembutsu H, Nakamura Y. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J. Hum. Genet. 58(6), 327–333 (2013).Crossref, Medline, CAS, Google Scholar
71 Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial. J. Natl Cancer Inst. 104(16), 1264; author reply 1266–1268 (2012).Crossref, Medline, CAS, Google Scholar
72 Hoskins JM, Carey LA, Mcleod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576–586. (2009).Crossref, Medline, CAS, Google Scholar
73 Lash TL, Rosenberg CL. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J. Clin. Oncol. 28(8), 1273–1275 (2010).Crossref, Medline, CAS, Google Scholar
74 Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312–9318 (2005).Crossref, Medline, CAS, Google Scholar
75 Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25(33), 5187–5193 (2007).Crossref, Medline, CAS, Google Scholar
76 Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, Flaws JA. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 217(1), 61–72 (2005).Crossref, Medline, CAS, Google Scholar
77 Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83(2), 322–327 (2008).Crossref, Medline, CAS, Google Scholar
78 Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79(1), 103–113 (2006).Crossref, Medline, CAS, Google Scholar
79 Kiyotani K, Mushiroda T, Tsunoda T et al. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum. Mol. Genet. 21(7), 1665–1672 (2012).Crossref, Medline, CAS, Google Scholar
80 Grabinski JL, Smith LS, Chisholm GB et al. Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Res. Treat. 95(1), 13–16 (2006).Crossref, Medline, CAS, Google Scholar
81 Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383–391 (2001).Crossref, Medline, CAS, Google Scholar
82 Murdter TE, Schroth W, Bacchus-Gerybadze L et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89(5), 708–717 (2011).Crossref, Medline, CAS, Google Scholar
83 Gjerde J, Geisler J, Lundgren S et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10, 313 (2010).Crossref, Medline, Google Scholar
84 Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 54(10), 1311–1331 (2002).Crossref, Medline, CAS, Google Scholar
85 Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab. Pharmacokinet. 17(1), 23–33 (2002).Crossref, Medline, CAS, Google Scholar
86 Kisanga ER, Mellgren G, Lien EA. Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. Anticancer Res. 25(6C), 4487–4492 (2005).Medline, CAS, Google Scholar

Vol. 16, No. 3

Metrics

Downloaded 424 times

History

Published online 25 February 2015

Published in print March 2015

Information

Keywords

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict withthe subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistant was utilized in the production of the manuscript.

PDF download

Pharmacogenomics toward personalized tamoxifen therapy for breast cancer

Abstract

References